FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003292783> ?p ?o ?g. }

• W2003292783 endingPage "27" @default.
• W2003292783 startingPage "22" @default.
• W2003292783 abstract "To determine the maximum-tolerated dose (MTD) and toxicity profile of the novel anticancer agent, 2-methoxyestradiol (2ME2) administered orally, in patients with solid tumors.Twenty patients with refractory solid tumors were enrolled. 2ME2 was given orally starting at 400 mg bid with dose escalation until 3000 mg bid. Tumor biopsies were taken before and after starting the drug to assess for microvessel density by CD 31 and cell proliferation by Ki67 immunohistochemistry. Serial plasma samples collected up to 50 hours after first single oral dose for characterization of pharmacokinetics, were analyzed using liquid chromatography tandem mass-spectrometry.Eleven men and nine women received 2ME2 at dose levels of 400 mg bid (n = 3), 800 mg bid (n = 3), 1600 mg bid (n = 6), 2200 mg bid (n = 5) and 3000 mg bid (n = 3). There were no dose limiting toxicities, therefore the MTD was not defined. There was one episode of grade 4 angioedema in the 1600 mg bid dose level 38 days into 2ME2 treatment. Other toxicities were mild to moderate. A patient with clear cell carcinoma of the ovary had a partial response at 1600 mg bid dose level lasting over three years.MTD for 2ME2 was not reached at dose of 3000 mg bid. The trial was closed due to extremely low plasma concentrations of 2ME2 relative to the doses administered. 2ME2 treatment had no effect on microvessel density (CD31 immunostaining) and cell proliferation (Ki-67 immunostaining). A new formulation of 2ME2 with improved bioavailability is currently being developed." @default.
• W2003292783 created "2016-06-24" @default.
• W2003292783 creator A5001321994 @default.
• W2003292783 creator A5003357684 @default.
• W2003292783 creator A5003770647 @default.
• W2003292783 creator A5005621340 @default.
• W2003292783 creator A5026507649 @default.
• W2003292783 creator A5027334479 @default.
• W2003292783 creator A5030037733 @default.
• W2003292783 creator A5040379801 @default.
• W2003292783 creator A5044239219 @default.
• W2003292783 creator A5047689869 @default.
• W2003292783 creator A5065279964 @default.
• W2003292783 creator A5070669850 @default.
• W2003292783 creator A5073536820 @default.
• W2003292783 creator A5084505373 @default.
• W2003292783 date "2006-01-16" @default.
• W2003292783 modified "2023-10-01" @default.
• W2003292783 title "Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors" @default.
• W2003292783 cites W1758017998 @default.
• W2003292783 cites W1782483823 @default.
• W2003292783 cites W1789842795 @default.
• W2003292783 cites W1910056530 @default.
• W2003292783 cites W1982341204 @default.
• W2003292783 cites W1983414305 @default.
• W2003292783 cites W1983964043 @default.
• W2003292783 cites W1998948981 @default.
• W2003292783 cites W2001282311 @default.
• W2003292783 cites W2015344488 @default.
• W2003292783 cites W2034426069 @default.
• W2003292783 cites W2064038200 @default.
• W2003292783 cites W2078016671 @default.
• W2003292783 cites W2080649751 @default.
• W2003292783 cites W2081124965 @default.
• W2003292783 cites W2082508000 @default.
• W2003292783 cites W2111700893 @default.
• W2003292783 cites W2116468415 @default.
• W2003292783 cites W2118033135 @default.
• W2003292783 cites W2123731765 @default.
• W2003292783 cites W2132219414 @default.
• W2003292783 cites W2142657147 @default.
• W2003292783 cites W2166082449 @default.
• W2003292783 cites W2166435019 @default.
• W2003292783 cites W2184749303 @default.
• W2003292783 cites W2325343629 @default.
• W2003292783 cites W2792932704 @default.
• W2003292783 cites W588881245 @default.
• W2003292783 doi "https://doi.org/10.4161/cbt.5.1.2349" @default.
• W2003292783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16357512" @default.
• W2003292783 hasPublicationYear "2006" @default.
• W2003292783 type Work @default.
• W2003292783 sameAs 2003292783 @default.
• W2003292783 citedByCount "144" @default.
• W2003292783 countsByYear W20032927832012 @default.
• W2003292783 countsByYear W20032927832013 @default.
• W2003292783 countsByYear W20032927832014 @default.
• W2003292783 countsByYear W20032927832015 @default.
• W2003292783 countsByYear W20032927832016 @default.
• W2003292783 countsByYear W20032927832017 @default.
• W2003292783 countsByYear W20032927832018 @default.
• W2003292783 countsByYear W20032927832019 @default.
• W2003292783 countsByYear W20032927832020 @default.
• W2003292783 countsByYear W20032927832021 @default.
• W2003292783 countsByYear W20032927832022 @default.
• W2003292783 countsByYear W20032927832023 @default.
• W2003292783 crossrefType "journal-article" @default.
• W2003292783 hasAuthorship W2003292783A5001321994 @default.
• W2003292783 hasAuthorship W2003292783A5003357684 @default.
• W2003292783 hasAuthorship W2003292783A5003770647 @default.
• W2003292783 hasAuthorship W2003292783A5005621340 @default.
• W2003292783 hasAuthorship W2003292783A5026507649 @default.
• W2003292783 hasAuthorship W2003292783A5027334479 @default.
• W2003292783 hasAuthorship W2003292783A5030037733 @default.
• W2003292783 hasAuthorship W2003292783A5040379801 @default.
• W2003292783 hasAuthorship W2003292783A5044239219 @default.
• W2003292783 hasAuthorship W2003292783A5047689869 @default.
• W2003292783 hasAuthorship W2003292783A5065279964 @default.
• W2003292783 hasAuthorship W2003292783A5070669850 @default.
• W2003292783 hasAuthorship W2003292783A5073536820 @default.
• W2003292783 hasAuthorship W2003292783A5084505373 @default.
• W2003292783 hasConcept C112705442 @default.
• W2003292783 hasConcept C121608353 @default.
• W2003292783 hasConcept C126322002 @default.
• W2003292783 hasConcept C2776260442 @default.
• W2003292783 hasConcept C2777292972 @default.
• W2003292783 hasConcept C2777477808 @default.
• W2003292783 hasConcept C2780873365 @default.
• W2003292783 hasConcept C29730261 @default.
• W2003292783 hasConcept C71924100 @default.
• W2003292783 hasConcept C90924648 @default.
• W2003292783 hasConcept C98274493 @default.
• W2003292783 hasConceptScore W2003292783C112705442 @default.
• W2003292783 hasConceptScore W2003292783C121608353 @default.
• W2003292783 hasConceptScore W2003292783C126322002 @default.
• W2003292783 hasConceptScore W2003292783C2776260442 @default.
• W2003292783 hasConceptScore W2003292783C2777292972 @default.
• W2003292783 hasConceptScore W2003292783C2777477808 @default.
• W2003292783 hasConceptScore W2003292783C2780873365 @default.

• next